Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trialChiara Cremolini, Filippo Pietrantonio, Roberto Bordonaro et al.|The Lancet Oncology|2020Cited by 322
Carboplatin-based doublet plus bevacizumab beyond progression versus carboplatin-based doublet alone in patients with platinum-sensitive ovarian cancer: a randomised, phase 3 trialSandro Pignata, I. L. Ray-Coquard, Domenica Lorusso et al.|The Lancet Oncology|2021Cited by 148
Membrane IL-18 identifies a human macrophage subset with distinct proteomic and functional traitsChiara Vitale, Roberta Castriconi, Andrea Petretto et al.|OncoImmunology|2025Cited by 1